New focus for BioNTech beyond Covid-19

Report this content

Few in the biotech world have missed the German wonder BioNTech’s success story in recent years. The success of their Covid-19 vaccine put the German development company on the map and led to a billion-dollar cash flow that few companies can match. However, the company has more strings to its bow and here BioStock looks at what to expect next.

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

New focus for BioNTech beyond Covid-19
Tweet this